Приказ основних података о документу
HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review
dc.creator | Gluvić, Zoran | |
dc.creator | Obradović, Milan M. | |
dc.creator | Lačković, Milena | |
dc.creator | Samardžić, Vladimir S. | |
dc.creator | Tica Jevtic, Jelena | |
dc.creator | Essack, Magbubah | |
dc.creator | Bajić, Vladimir B. | |
dc.creator | Isenović, Esma R. | |
dc.date.accessioned | 2020-02-11T23:04:06Z | |
dc.date.available | 2020-02-11T23:04:06Z | |
dc.date.issued | 2019 | |
dc.identifier.issn | 0269-4727 | |
dc.identifier.uri | https://vinar.vin.bg.ac.rs/handle/123456789/8484 | |
dc.description.abstract | What is known and objective: The HbA1C marker used in assessing diabetes control quality is not sufficient in diabetes patients with thalassaemia. Case description: A male diabetic patient with thalassaemia was hospitalized due to distal neuropathic pain, right toe trophic ulcer, unacceptable five-point glycaemic profile and recommended HbA1C value. After simultaneously initiated insulin therapy and management of ulcer by hyperbaric oxygen, the patient showed improved glycaemic control and ulcer healing, which led to the patient's discharge. What is new and conclusion: In thalassaemia and haemoglobinopathies, due to discrepancies in the five-point glycaemic profile and HbA1C values, it is necessary to measure HbA1C with a different method or to determine HbA1C and fructosamine simultaneously. © 2019 The Authors. Journal of Clinical Pharmacy and Therapeutics Published by John Wiley & Sons Ltd. | en |
dc.language.iso | en | |
dc.relation | info:eu-repo/grantAgreement/MESTD/Basic Research (BR or ON)/173033/RS// | |
dc.relation | KAUST [4129] | |
dc.relation | KAUST Base Research Fund [BAS/1/1606-01-01] | |
dc.relation | KAUST Office of Sponsored Research (OSR) [FCC/1/1976-17-01] | |
dc.rights | openAccess | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc/4.0/ | |
dc.source | Journal of Clinical Pharmacy and Therapeutics | |
dc.subject | diabetes | en |
dc.subject | fructosamine | en |
dc.subject | glycaemic control | en |
dc.subject | glycaemic profile | en |
dc.subject | HbA1C | en |
dc.subject | thalassaemia | en |
dc.title | HbA1C as a marker of retrograde glycaemic control in diabetes patient with co-existed beta-thalassaemia: A case report and a literature review | en |
dc.type | article | en |
dc.rights.license | BY-NC | |
dcterms.abstract | Бајиц, В Б; Обрадовиц, М; Исеновиц, Е Р; Глувиц, З; Лацковиц, М; Самардзиц, В; Тица Јевтиц, Ј; Ессацк, М; | |
dc.rights.holder | © 2019 The Authors. Journal of Clinical Pharmacy and Therapeutics Published by John Wiley & Sons Ltd. | |
dc.citation.volume | 45 | |
dc.citation.issue | 2 | |
dc.citation.spage | 379 | |
dc.citation.epage | 383 | |
dc.identifier.wos | 000496728900001 | |
dc.identifier.doi | 10.1111/jcpt.13073 | |
dc.citation.rank | M23 | |
dc.identifier.pmid | 31736110 | |
dc.type.version | publishedVersion | |
dc.identifier.scopus | 2-s2.0-85075520848 |
Документи
Овај документ се појављује у следећим колекцијама
-
Radovi istraživača
Researchers' publications